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INTRODUCTION
Ovarian cancer is a major burden in the field of
gynecology oncology, due to high rate of mortality
resulted from this cancer.1 Increasing ratio of
morbidity and mortality in ovarian cancer patients
is due to progression of disease that shows no
symptoms found until metastasis. 70% of women
with ovarian cancer are diagnosed at advanced
stage. The five year survival rate of ovarian cancer
is 85% when diagnosed at early stage (stage I and
II), but may decrease to less than 20% if diagnosed
at advanced stage (stage III or IV).2
Abstract
Objective: To evaluate the accuracy of hK6, HE4, and CA125 in
predicting the malignancy of ovarian mass.
Methods: The design of this study was cross-sectional. This study
was conducted in the Obstetrics and Gynecology Clinic, Sanglah
Hospital, Denpasar, between the period of September 2014 and
August 2016. Samples were all patients with ovarian tumors who
underwent surgery at Sanglah Hospital, Denpasar. Data analysis
was performed using McNemar and chi square test in SPSS for
windows version 17.0.
Results: 22 samples were obtained. P > 0.05 value of age and parity
variables indicated no differences between the two groups. There is
no accuracy differences (sensitivity, specificity, positive predictive
value, negative predictive value) of hK6 compared to histopathology
examination in diagnosing ovarian cancer (p = 1). There is no
accuracy differences (sensitivity, specificity, positive predictive
value, negative predictive value) of HE4 compared to histopathology
examination in diagnosing ovarian cancer (p = 1). There is no
accuracy difference (sensitivity, specificity, positive predictive value,
negative predictive value) of CA125 compared to histopathology
examination in diagnosing ovarian cancer (p = 0.687).
Conclusion: There was no accuracy differences (sensitivity,
specificity, positive predictive value, negative predictive value)
found between hK6, CA125, HE4 compared to histopathology
examination in predicting ovarian cancer.
[Indones J Obstet Gynecol 2017; 5-2: 110-113]
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Abstrak
Tujuan: Untuk mengetahui akurasi hK6, CA125 dan HE4 dalam
memprediksi keganasan ovarium pada massa ovarium.
Metode: Rancangan penelitian ini adalah uji diagnostik (cross sec-
tional) yang dilaksanakan di Poliklinik Kebidanan dan KandunganRSUP Sanglah, Denpasar. Sampel penelitian ini adalah semua pen-
derita dengan tumor ovarium yang datang ke Poliklinik Kebidanan
dan Kandungan RSUP Sanglah dan menjalani operasi di RSUPSanglah, Denpasar. Pengambilan sampel dilakukan dengan cara
consecutive sampling mulai September 2014 sampai Agustus 2016.Analisis data memakai uji Chi Square dan McNemar dengan bantuan
SPSS for windows 17.0 version.
Hasil: Didapatkan sebanyak 22 sampel penelitian variabel usia dan
paritas didapatkan nilai p > 0,05, yang menyatakan bahwa tidak
adanya perbedaan antara kedua kelompok. Tidak ada perbedaankurasi hK6 (sensitivitas, spesivisitas, nilai prediksi positif, nilai
prediksi negatif) dibandingkan dengan hasil pemeriksaan histo-patologi dalam mendiagnosis kanker ovarium (p=1). Tidak ada
perbedaan kurasi HE4 (sensitivitas, spesivisitas, nilai prediksi
positif, nilai prediksi negatif) dibandingkan dengan hasil peme-riksaan histopatologi dalam mendiagnosis kanker ovarium (p=1).
Tidak ada perbedaan kurasi CA125 (sensitivitas, spesifisitas, nilai
prediksi positif, nilai prediksi negatif) dibandingkan dengan hasilpemeriksaan histopatologi dalam mendiagnosis kanker ovarium
(p=0,687).
Kesimpulan: Tidak ada perbedaan kurasi antara hK6, CA125, HE4
(sensitivitas, spesifisitas, nilai prediksi positif, nilai prediksi negatif)dibandingkan dengan hasil pemeriksaan histopatologi dalam mem-
prediksi kanker ovarium.
[Maj Obstet Ginekol Indones 2017; 5-2: 110-113]
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Serum of CA125 tumor marker to predict the
presence of malignancy in patients with ovarian
mass has lower sensitivity and specificity in pre
and postmenopausal women.3 Several studies
conducted to diagnose ovarian cancer in patients
with ovarian mass using tumor marker HE4 and
combination of HE4 and CA125 have shown
that HE4 has higher sensitivity and specificity
compared to CA125.4
Kallikrein 6 gene is a trypsin-like serine protease
of human gene, family kallikrein that has great
potential to be developed as a tool for early
detection for ovarian cancer and various
preliminary research have been conducted to
support towards it and result of the research can
be used as rationale that hK6 can be used as a
medium or tool for early detection of ovarian
cancer.5
Based on explanation elaborated above,
assessment of the correlation or relationship
between hK6 with ovarian cancer will be
performed. This study is expected to be a
reference or additional consideration to support
usage hK6 as the early detection of ovarian cancer
diagnostic.
METHOD
We used cross-sectional study design. This study
was conducted at the Obstetrics and Gynecology
Clinic, Sanglah Hospital, Denpasar, during the
period between September 2014 and August
2016. The subjects were all patients with ovarian
tumors who came to Obstetrics Clinic of Sanglah
Hospital and underwent surgery in Sanglah
Hospital, Denpasar. Data analysis was performed
using SPSS for Windows version 17.0.
RESULT
In this study, T-independent test was conducted
toward age and parity variable between the two
groups. As seen in Table 1, p value> 0.05 of age
and parity was obtained, indicated no differences
between both groups.
To determine diagnostic test of hK6 toward
histopathology in the diagnosis of ovarian cancer,
it was analyzed using Chi-Square test. The results
of the analysis are presented in the following
table.
Table above with 2x2 cross table, showed 80.0%
sensitivity, 75.0% specificity, 72.7% positive
predictive value, 81.8% negative predictive value,
27.3% false positive, 18.2% false negative values,
and 77.3% accuracy. McNemar test showed no
accuracy differences of hK6 (sensitivity, specificity,
positive predictive value, negative predictive
value) compared to histopathology examination in
diagnosing ovarian cancer (p = 1.00)
To determine diagnostic test of HE4 compared
to histopathology in diagnosis of ovarian cancer,
Chi-Square test analysis was conducted. Results are
presented in Table 3.
Table 1. General and Parity Characteristics Comparison between both Groups
Risk factor Malignancy group (n=10) Benign tumor group (n=12) p
Mean DS Mean DS
Age (year) 52.80 16.72 50.50 14.94 0.737
Parity 2.10 1.10 2.08 1.88 0.981
Table 2. Diagnostic Test of hK6 toward Histopathology in Diagnosing Ovarian Cancer
Ovarian cancer Total
Malignant Benign
hK6
High 8 3 11
Low 2 9 11
Total 10 12 22
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Table above with a 2x2 cross table showed
70.0% sensitivity, 83.3% specificity, 77.8% positive
predictive value, 76.9% negative predictive value,
22.2% false positive, 23.1% false negative values,
and 77.3% accuracy. McNemar test showed no
differences of accuracy (sensitivity, specificity,
positive predictive value, negative predictive
value) HE4 compared to histopathology exami-
nation in diagnosing ovarian cancer (p = 1.00).
To determine diagnostic test of CA125 com-
pared to histopathology in diagnosis of ovarian
cancer, Chi-Square test analysis was conducted.
The results of analysis is presented in Table 4.
Table above with a 2x2 cross table showed
60.0% sensitivity, 83.3% specificity, 75.0% positive
predictive value, 71.4%, negative predictive value,
25.0%, false positive, 28.6%, false negative values,
and 72.7% accuracy. McNemar test showed no
accuracy differences (sensitivity, specificity, posi-
tive predictive value, negative predictive value) of
HE4 compared to histopathology examination in
diagnosing ovarian cancer (p = 1.00).
DISCUSSION
Result of the research revealed p value > 0.05 of
age and parity variable, suggesting no differences
between the two groups.
Diagnostic test of HK6 toward histopathology in
diagnosis of ovarian cancer revealed sensitivity,
specificity, positive predictive value, negative
predictive value, false positive value, negative
value, and accuracy of 80%, 75%, 72.7%, 81.8%,
27.3%, 18.2%, and 77.3%, respectively. McNemar
test showed p-value of diagnostic tests of hK6
toward histopathology examination in diagnosing
ovarian cancer is p = 1.00. It shows that no
accuracy differences (sensitivity, specificity,
positive predictive value, negative predictive
value) of hK6 compared to histopathology
examination in diagnosing ovarian cancer. This can
be explained that, in ovarian cancer, the increment
of hK5, hK6, hK8, hK10, hK11 and hK14 in serum
make kallikrein become a potential biomarker.
Several studies on the association of hK6 with
ovarian cancer showed that among many types of
cancer, only in ovarian cancer, hK6 levels in
circulation showed remarkable increase.6
Diagnostic test of HE4 toward histopathology
showed 70.0% sensitivity, 83.3% specificity,
77.8% positive predictive value, 76.9% negative
predictive value, 22.2% false positive, 23.1% false
negative values, and 77.3% accuracy. McNemar
test showed no differences of accuracy (sensitivity,
specificity, positive predictive value, negative
predictive value) HE4 compared to histopatho-
logy examination in diagnosing ovarian cancer
(p = 1.00). This result is supported by another
research conducted Wang et al which examined
HE4 level in the differential diagnosis of pelvic
mass in the population of Chinese women. The
Table 3. Diagnostic Test of HE4 toward Histopathology in Diagnosing Ovarian Cancer
Ovarian cancer Total
Malignant Benign
HE4
High 7 2 9
Low 3 10 13
Total 10 12 22
Table 4. Diagnostic Test of CA125 toward Histopathology in Diagnosing Ovarian Cancer
Ovarian cancer Total
Malignant Benign
CA125
High 6 2 8
Low 4 10 14
Total 10 12 22
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study demonstrated that the sensitivity and
specificity of HE4 were 86.7% and 98.0%, respec-
tively.7
Diagnostic test of CA125 toward histopathology
showed 70.0% sensitivity, 83.3% specificity,
77.8% positive predictive value, 76.9% negative
predictive value, 22.2% false positive, 23.1% false
negative values, and 77.3% accuracy. McNemar
test showed no differences of accuracy (sensitivity,
specificity, positive predictive value, negative
predictive value) CA125 compared to histopa-
thology examination in diagnosing ovarian cancer
(p = 1.00). In initial report, it is known that level
of CA125 increased by about 80% in women with
advanced ovarian cancer and only 1-2% in the
normal population. While in stage I ovarian cancer,
CA125 level increased less than 50%. Specificity of
CA125 is also low in differentiating between
benign and malignant cases. In a retrospective
study of 9233 women, sensitivity 62% of CA125
was obtained.8
CONCLUSION
There were no accuracy differences (sensitivity,
specificity, positive predictive value, negative pre-
dictive value) between hK6, CA125, HE4 compared
to histopathology examination in diagnosing
ovarian cancer. Each of hK6, CA125 and HE4 value
can be used as an ovarian cancer biomarker.
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